Clinical trial
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in…
NCT00364858 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00364858 |
|---|---|
| Title | Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease |
| Official title | A Phase IV, Multicenter, Randomized, Dose Frequency Study of the Safety and Efficacy of Cerezyme® Infusions Every Four Weeks Versus Every Two Weeks in the Maintenance Therapy of Patients With Type 1 Gaucher Disease |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gaucher Disease, Type 1, Cerebroside Lipidosis Syndrome, Glucocerebrosidase Deficiency Disease, Glucosylceramide Beta-Glucosidase Deficiency Disease, Non-Neuronopathic Form |
| Intervention type | Drug |
| Interventions | Cerezyme |
| Enrollment | 95 |
| Start date | Dec 1, 2001 |
| Completion | Feb 1, 2007 |
| First posted | Aug 16, 2006 |
| Last update posted | Apr 3, 2015 |
| Countries | Brazil, Canada, Italy, Poland, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: